Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Expands bioprocessing footprint across Asia
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
HYMPAVZI’s safety profile was generally favorable
While Merck can appeal, Halozyme said it expects the order to hold
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Subscribe To Our Newsletter & Stay Updated
